Abstract:Background: Small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) of the lung, and extrapulmonary NEC (epNEC) are difficult-to-treat, aggressive tumors with limited treatment options. Purpose: Many pts relapse and have poor outcomes after standard of care platinum-based chemotherapy ± immunotherapy, underscoring the need for better therapies. BI 764532, a humanized IgG-like T-cell engager, binds to delta-like ligand 3 (DLL3) on the cell surface of these tumors and on CD3 on T cells, consequently promoting T-cell-mediated cytotoxicity. In an ongoing first-in-human trial, BI 764532 exhibited efficacy and manageable tolerability in pts with DLL3-positive SCLC, LCNEC of the lung, and epNEC (NCT04429087). We describe a planned phase 2 dose optimization trial to assess safety/efficacy of 2 different doses of BI 764532 monotherapy in pts with progressive/relapsed SCLC, epNEC, or LCNEC of the lung (NCT05882058). Experimental design: The trial will recruit adult pts (n=~120; ~70 sites; ~15 countries) with pathologically confirmed relapsed/refractory SCLC, epNEC, or LCNEC of the lung who have received ≥2 (SCLC) or ≥1 (epNEC/LCNEC) prior lines of therapy, including ≥1 platinum-based regimen. Pts with mixed tumor histology are permitted if the SCLC/NEC component is predominant (≥50% of tumor tissue). Pts will be randomized 1:1 to receive 1 of 2 dose levels of IV BI 764532 (3-week cycles) stratified by tumor type (n=~60/arm). Treatment will continue until disease progression, undue toxicity, withdrawal of consent or any other documented criteria for stopping treatment (maximum treatment duration: 36 months). 2 interim dose-selection analyses are planned after 30 pts per dose have been followed for ≥6 and ≥12 weeks or have stopped treatment. A third interim efficacy analysis will be conducted when 60 pts per dose have been followed for ≥12 weeks or have stopped treatment. Key exclusion criteria: Eastern Cooperative Oncology Group performance status ≥2; untreated/symptomatic brain metastases or leptomeningeal disease; active/history of interstitial lung disease/pneumonitis; previous DLL3-targeting treatment; treatment with other anticancer drugs <4 weeks prior to first administration of BI 764532; unresolved toxicity from prior treatment; immunodeficiency diagnosis; intake of immunosuppressive therapy ≤7 days prior to first administration of BI 764532. Primary endpoints: objective response via Response Evaluation Criteria in Solid Tumors v1.1; occurrence of treatment-emergent adverse events (TEAEs). Secondary endpoints: duration of objective response, progression-free survival, disease control, overall survival, patient-reported outcomes, and TEAEs leading to discontinuation. Further endpoints: pharmacokinetics, and prespecified and exploratory biomarker analysis. Citation Format: Valentina Gambardella, Alastair Greystoke, Martin Reck, Meiruo Liu, Martha Mueller, Ulrich Duenzinger, Emily B. Bergsland, Taofeek Owonikoko. DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr CT279.

Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study

Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer

Tarlatamab: First Approval

Abstract 7164: Exposure-efficacy and exposure-safety relationships of tarlatamab to inform dose selection and benefit-risk assessment in patients with advanced small cell lung cancer (SCLC)

Abstract 7167: Impact of patient specific factors on exposures of tarlatamab, a half-life extended DLL3-directed bispecific T-cell engager in patients with advanced small cell lung cancer

Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.

Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).

First-in-class T cell engager approved for lung cancer

Abstract CT279: DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report

A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

Abstract 5550: QLS31904: An anti-DLL3/CD3 bispecific antibody for T cell immunotherapy of small cell lung cancer

Abstract CT090: DAREONTM-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas

A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.

DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).